Carregant...
State-of-the-art pharmacological approaches to reduce chorea in Huntington’s Disease
INTRODUCTION: Chorea is a common motor manifestation of Huntington’s disease (HD). Two vesicular monoamine transporter type 2 (VMAT-2) inhibitors have been approved by the FDA for treatment of HD chorea, and a third is currently being assessed in a phase 3 trial. Antipsychotic therapies are used off...
Guardat en:
| Publicat a: | Expert Opin Pharmacother |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8222076/ https://ncbi.nlm.nih.gov/pubmed/33550875 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14656566.2021.1876666 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|